shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)

    NOT-CA-24-053

    Opening date 21 May 2024, 12:00AM

    Closing date N/A

    Funding Opportunity Number: NOT-CA-24-053

    Opportunity Category: Discretionary

    Expected Number of Awards: 5

    CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research,93.394 -- Cancer Detection and Diagnosis Research,93.395 -- Cancer Treatment Research,93.396 -- Cancer Biology Research,93.399 -- Cancer Control

    Cost Sharing or Matching Requirement: No

    Posted Date: May 21, 2024 12:00:00 AM EDT

    Closing Date: N/A

    Estimated Total Program Funding: 4900000

    Award Ceiling: $650000

    Eligible Applicants: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Private institutions of higher education,County governments,Public housing authorities/Indian housing authorities,Independent school districts,For profit organizations other than small businesses,State governments,Native American tribal governments (Federally recognized),Others (see text field entitled "Additional Information on Eligibility" for clarification),Public and State controlled institutions of higher education,Small businesses

    Description: The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative. It aims to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research laboratory, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in the early Fall of 2024, with an expected application due date in November 2024. The NOFO will utilize the U01 mechanism for �Research Project Cooperative Agreement (Clinical Trial Not Allowed)�. Potential applicants are encouraged to view the presentation of this initiative to the NCI Board of Scientific Advisors (BSA), available at: (https://videocast.nih.gov/watch=54423) beginning at 1 hour, 32 minutes, 52 seconds. Presentation slides are downloadable at https://deainfo.nci.nih.gov/advisory/bsa/0324/Maas.pdf. �

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept